Modern Antiemetic Regimens in Highly Emetogenic Chemotherapy (HEC): Quadruple Prophylaxis (NK1 RA, 5-HT3 RA, Dexamethasone, Olanzapine)

1. Neurobiology of Chemotherapy-Induced Nausea & Vomiting (CINV)

CINV is mediated via two primary pathways: 1) The Peripheral Acute Pathway (0–24 hours post-chemo): Triggered by free radical damage to enterochromaffin cells in the gastrointestinal mucosa, releasing serotonin (5-HT) which stimulates vagal 5-HT3 receptors; 2) The Central Delayed Pathway (24–120 hours post-chemo): Driven by substance P binding to Neurokinin-1 (NK1) receptors in the area postrema / chemoreceptor trigger zone (CTZ) of the brainstem. In addition, dopamine (D2) and histamine pathways contribute significantly to persistent breakthrough nausea.

2. The Evidence-Based Quadruple Prophylaxis Regimen (MASCC / ASCO / ESMO)

For Highly Emetogenic Chemotherapy (HEC: Cisplatin >=50 mg/m², Anthracycline + Cyclophosphamide / AC regimens, Carboplatin AUC >=4, Dacarbazine), quadruple antiemetic prophylaxis achieves complete protection from emesis in over 85% of patients:

1. 1. NK1 Receptor Antagonist: Aprepitant (125 mg PO Day 1, 80 mg PO Days 2-3) or Fosaprepitant (150 mg IV Day 1) or Netupitant (NEPA combination). Blocks central substance P signaling.

2. 2. 5-HT3 Receptor Antagonist: Palonosetron (0.25 mg IV Day 1) or Ondansetron (8–16 mg IV Day 1). Palonosetron is preferred due to its 40-hour half-life and allosteric receptor binding.

3. 3. Dexamethasone: 12 mg PO/IV Day 1, followed by 8 mg PO daily on Days 2–4 (dose-reduced to 12 mg due to Aprepitant CYP3A4 inhibition).

4. 4. Olanzapine (Atypical Antipsychotic): 5 mg to 10 mg PO nightly on Days 1–4. Blocks multiple neurotransmitter receptors (D2, 5-HT2C, 5-HT3, alpha-1, H1), eliminating refractory nausea.

"No cancer patient should experience vomiting during modern chemotherapy. Adding low-dose Olanzapine to NK1, 5-HT3, and Dexamethasone has made nausea-free cancer care an achievable daily standard." — Dr. Neha Gupta

3. Management of Breakthrough CINV

For breakthrough nausea occurring despite guideline prophylaxis: administer an antiemetic from an alternate mechanistic class—e.g., Metoclopramide (10–20 mg q6-8h), Prochlorperazine (10 mg q6h), or Lorazepam (0.5–1 mg PO/IV for anticipatory anxiety component). Re-evaluate hydration and electrolyte balance immediately.

4. Peer-Reviewed References & Clinical Guidelines

1. Navari RM, Qin R, Ruddy KJ, et al. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. New England Journal of Medicine (NEJM), 2016; 375: 134-142.

2. Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO Guideline Update. Journal of Clinical Oncology (JCO), 2020; 38(24): 2782-2797.

3. Multinational Association of Supportive Care in Cancer (MASCC) / European Society for Medical Oncology (ESMO) Antiemetic Guidelines, 2024 Updated Recommendations.